Department of Biomedical Science, Faculty of Medicine and Health Sciences, University of Putra Malaysia, Serdang, Malaysia.
Department of Pathology, Faculty of Medicine and Health Sciences, University of Putra Malaysia, Serdang, Malaysia.
Adv Med Sci. 2023 Sep;68(2):359-365. doi: 10.1016/j.advms.2023.09.008. Epub 2023 Sep 25.
Prostate cancer (PC) is the second most common cancer in men worldwide. Homologous recombination repair (HRR) gene defects have been identified in a significant proportion of metastatic castration-resistant PC (mCRPC) and are associated with an increased risk of PC and more aggressive PC. Importantly, it has been well-documented that poly ADP-ribose polymerase (PARP) inhibition in cells with HR deficiency (HRD) can cause cell death. This has been exploited for the targeted treatment of PC patients with HRD by PARP inhibitors. Moreover, it has been shown that platinum-based chemotherapy is more effective in mCRPC patients with HRR gene alterations. This review highlights the prognosis and therapeutic implications of HRR gene alterations in PC.
前列腺癌（PC）是全球男性中第二常见的癌症。在很大一部分转移性去势抵抗性前列腺癌（mCRPC）中已经发现同源重组修复（HRR）基因缺陷，并且与前列腺癌风险增加和更具侵袭性的前列腺癌相关。重要的是，已经有充分的文献记载，HR 缺陷（HRD）细胞中的聚 ADP-核糖聚合酶（PARP）抑制会导致细胞死亡。这已被用于 HRD 的前列腺癌患者的靶向治疗，通过 PARP 抑制剂。此外，已经表明，在 HRR 基因改变的 mCRPC 患者中，铂类化疗更有效。这篇综述强调了 HRR 基因改变在 PC 中的预后和治疗意义。
